Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165995 | 0.98 | GABRA1 (0.46) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| Hydrochloric Acid SCHEMBL8136588 | 0.95 | GABRA1 (0.44) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| Ammonia Solution, Strong SCHEMBL7468688 | 0.95 | GABRA1 (0.44) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL11034682 | 0.88 | GABRA1 (0.43) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL17745129 | 0.86 | GABRA1 (0.44) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL2213750 | 0.86 | GABRA1 (0.44) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| SCHEMBL4609225 | 0.86 | GABRA1 (0.42) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| Pyrene SCHEMBL5678493 | 0.86 | ALDH1A1 (0.41) | GABRA1GABRB2CYP3A4TSHRTAAR1 | |
| SCHEMBL6308607 | 0.84 | PNMT (0.40) | GABRA1GABRB2CYP3A4TSHRPIK3CA | |
| Methylamine SCHEMBL27545014 | 0.83 | GABRA1 (0.55) | GABRA1GABRB2TAAR1HTR1ADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007743-B1 | METHODS FOR SYNTHESIZING AMMONIA BORANE | UNIV OHIO STATE (US) | 2013-06-12 | — | — | EP | claimed |
| CN-102796134-A | Preparation method for Maxacalcitol intermediate | GANSU HAOTIAN CHEMICAL TECHNOLOGY CO LTD | 2012-11-28 | — | — | CN | claimed |
| CN-103732578-B | quinolinyl glucagon receptor modulators | PFIZER INC. (US) | 2015-08-12 | — | — | CN | disclosed |
| CN-102605034-B | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-103732578-A | Quinolinyl glucagon receptor modulators | PFIZER | 2014-04-16 | — | — | CN | disclosed |
| CN-102378574-B | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA INC | 2013-11-20 | — | — | CN | disclosed |
| CN-103370306-A | Glucagon receptor modulators | PFIZER | 2013-10-23 | — | — | CN | disclosed |
| CN-102906071-A | Method for producing substituted pyridin-2-one | Bayer Pharma AG | 2013-01-30 | — | — | CN | disclosed |
| CN-102869667-A | Tricyclic pyridine derivatives, medicaments containing these compounds, their use and processes for their preparation | BOEHRINGER INGELHEIM INT | 2013-01-09 | — | — | CN | disclosed |
| CN-102796134-A | Preparation method for Maxacalcitol intermediate | GANSU HAOTIAN CHEMICAL TECHNOLOGY CO LTD | 2012-11-28 | — | — | CN | disclosed |
| CN-101119965-B | Tetralin and indane derivatives and uses thereof | HOFFMANN LA ROCHE | 2012-09-26 | — | — | CN | disclosed |
| CN-1980920-A | Thiophene derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-06-13 | — | — | CN | disclosed |
| CN-1964962-A | Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors | HOFFMANN LA ROCHE (CH) | 2007-05-16 | — | — | CN | disclosed |
| US-20050043341-A1 | 3-'Hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7 8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-02-24 | — | — | US | disclosed |
| US-6562976-B2 | Such as methyl-2-cyclopentyl-4-(4-fluorophenyl)-5-oxo-7,7-dimethyl-1,4,5,6,7,8 -hexahydroquinoline-3-carboxylate for treatment of arteriosclerosis and dyslipidaemias; condensation | BAYER AKTIENGESELLSCHAFT (DE) | 2003-05-13 | — | — | US | disclosed |
| US-20020165252-A1 | 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein | BAYER AKTIENGESELLSCHAFT | 2002-11-07 | — | — | US | disclosed |
| US-6291477-B1 | Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-18 | — | — | US | disclosed |
| CN-1307563-A | N-phenyl-N' -phenylpropylpiperazine derivatives and process for the preparation thereof | ZERIA PHARM CO LTD (JP) | 2001-08-08 | — | — | CN | disclosed |
| US-6207671-B1 | FOR TREATMENT OF HYPERTIPOPROTEINAEMIA, ARTERIOSCLEROSIS DYSLIPIDAEMIA | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6069148-A | ANTICHOLESTEROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043341-A1 | 3-'Hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7 8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors | CETP, MTTP, HDLBP | GABRA1 4694/4885GABRB2 4310/4885CYP3A4 392/4885 |
| US-20020165252-A1 | 4-phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein | CETP, LCAT, ACAT2 | GABRA1 4832/4885GABRB2 4737/4885CYP3A4 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.